{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T19:33:17Z","timestamp":1793043197263,"version":"4.5.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2015,2,1]],"date-time":"2015-02-01T00:00:00Z","timestamp":1422748800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of the American Academy of Child & Adolescent Psychiatry"],"published-print":{"date-parts":[[2015,2]]},"DOI":"10.1016\/j.jaac.2014.11.009","type":"journal-article","created":{"date-parts":[[2014,11,25]],"date-time":"2014-11-25T14:20:52Z","timestamp":1416925252000},"page":"126-137.e1","source":"Crossref","is-referenced-by-count":49,"title":["Efficacy and Safety of Paliperidone Extended Release in Adolescents With Schizophrenia: A Randomized, Double-Blind Study"],"prefix":"10.1016","volume":"54","author":[{"given":"Adam J.","family":"Savitz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosanne","family":"Lane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isaac","family":"Nuamah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srihari","family":"Gopal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Hough","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl","key":"10.1016\/j.jaac.2014.11.009_bib1","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1016\/j.jad.2012.02.030","article-title":"Antipsychotics in pediatric and adolescent patients: a review of comparative safety data","volume":"138","author":"Ben Amor","year":"2012","journal-title":"J\u00a0Affect Disord"},{"key":"10.1016\/j.jaac.2014.11.009_bib2","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1517\/14656566.9.12.2053","article-title":"Child and adolescent schizophrenia: pharmacological approaches","volume":"9","author":"Madaan","year":"2008","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.jaac.2014.11.009_bib3","doi-asserted-by":"crossref","first-page":"179","DOI":"10.2165\/11585350-000000000-00000","article-title":"Management of schizophrenia in children and adolescents: focus on pharmacotherapy","volume":"71","author":"Masi","year":"2011","journal-title":"Drugs"},{"key":"10.1016\/j.jaac.2014.11.009_bib4","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1176\/appi.ajp.157.10.1652","article-title":"Adult outcomes of child- and adolescent-onset schizophrenia: diagnostic stability and predictive validity","volume":"157","author":"Hollis","year":"2000","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.jaac.2014.11.009_bib5","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1097\/YCO.0b013e32833b027e","article-title":"Treatment of early-onset schizophrenia","volume":"23","author":"Mattai","year":"2010","journal-title":"Curr Opin Psychiatry"},{"key":"10.1016\/j.jaac.2014.11.009_bib6","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1093\/schbul\/sbt196","article-title":"Evidence base for using atypical antipsychotics for psychosis in adolescents","volume":"40","author":"Datta","year":"2014","journal-title":"Schizophr Bull"},{"key":"10.1016\/j.jaac.2014.11.009_bib7","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1093\/schbul\/sbm109","article-title":"Efficacy and tolerability of second-generation antipsychotics in children and adolescents with schizophrenia","volume":"34","author":"Kumra","year":"2008","journal-title":"Schizophr Bull"},{"issue":"Suppl 4","key":"10.1016\/j.jaac.2014.11.009_bib8","first-page":"26","article-title":"Assessing and maximizing the safety and tolerability of antipsychotics used in the treatment of children and adolescents","volume":"69","author":"Correll","year":"2008","journal-title":"J\u00a0Clin Psychiatry"},{"key":"10.1016\/j.jaac.2014.11.009_bib9","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1001\/jama.2009.1549","article-title":"Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents","volume":"302","author":"Correll","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.jaac.2014.11.009_bib10","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.schres.2008.01.028","article-title":"Typical and atypical antipsychotics differentially affect long-term incidence rates of the metabolic syndrome in first-episode patients with schizophrenia: a retrospective chart review","volume":"101","author":"De Hert","year":"2008","journal-title":"Schizophr Res"},{"key":"10.1016\/j.jaac.2014.11.009_bib11","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.euroneuro.2010.07.002","article-title":"Efficacy and safety of second-generation antipsychotics in children and adolescents with psychotic and bipolar spectrum disorders: comprehensive review of prospective head-to-head and placebo-controlled comparisons","volume":"21","author":"Fraguas","year":"2010","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1016\/j.jaac.2014.11.009_bib12","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1176\/appi.ajp.2008.08050756","article-title":"Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the Treatment of Early-Onset Schizophrenia Spectrum Disorders (TEOSS) study","volume":"165","author":"Sikich","year":"2008","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.jaac.2014.11.009_bib13","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1017\/S0033291709990407","article-title":"Weight gain in antipsychotic-naive patients: a review and meta-analysis","volume":"40","author":"Tarricone","year":"2010","journal-title":"Psychol Med"},{"key":"10.1016\/j.jaac.2014.11.009_bib14","series-title":"INVEGA\u00ae (paliperidone) Extended-release tablets full prescribing information","year":"2008"},{"key":"10.1016\/j.jaac.2014.11.009_bib15","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/j.biopsych.2011.06.021","article-title":"A\u00a0randomized, double-blind study of paliperidone extended-release in treatment of\u00a0acute schizophrenia in adolescents","volume":"70","author":"Singh","year":"2011","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.jaac.2014.11.009_bib16","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1089\/104454603322572651","article-title":"Effectiveness, safety, and tolerability of risperidone in adolescents with schizophrenia: an open-label study","volume":"13","author":"Zalsman","year":"2003","journal-title":"J\u00a0Child Adolesc Psychopharmacol"},{"key":"10.1016\/j.jaac.2014.11.009_bib17","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1097\/YCO.0b013e32835dcc2a","article-title":"Treatment of adolescents with early-onset schizophrenia spectrum disorders: in search of a rational, evidence-informed approach","volume":"26","author":"Schimmelmann","year":"2013","journal-title":"Curr Opin Psychiatry"},{"key":"10.1016\/j.jaac.2014.11.009_bib18","doi-asserted-by":"crossref","first-page":"572","DOI":"10.4088\/JCP.08m04421","article-title":"A\u00a028-week, randomized, double-blind study of olanzapine versus aripiprazole in the treatment of schizophrenia","volume":"70","author":"Kane","year":"2009","journal-title":"J\u00a0Clin Psychiatry"},{"key":"10.1016\/j.jaac.2014.11.009_bib19","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1176\/appi.ajp.2008.07061035","article-title":"A\u00a0multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia","volume":"165","author":"Findling","year":"2008","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.jaac.2014.11.009_bib20","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1097\/00004583-199707000-00021","article-title":"Schedule for Affective Disorders and Schizophrenia for School-Age Children\u2013Present and Lifetime Version (K-SADS-PL): initial reliability and validity data","volume":"36","author":"Kaufman","year":"1997","journal-title":"J\u00a0Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.jaac.2014.11.009_bib21","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1176\/appi.ajp.162.3.441","article-title":"Remission in schizophrenia: proposed criteria and rationale for consensus","volume":"162","author":"Andreasen","year":"2005","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.jaac.2014.11.009_bib22","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1089\/cap.2008.0144","article-title":"A\u00a06-week, randomized, double-blind, placebo-controlled study of the efficacy and safety of risperidone in adolescents with schizophrenia","volume":"19","author":"Haas","year":"2009","journal-title":"J\u00a0Child Adolesc Psychopharmacol"},{"key":"10.1016\/j.jaac.2014.11.009_bib23","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1089\/cap.2011.0092","article-title":"Efficacy and safety of quetiapine in adolescents with schizophrenia investigated in a 6-week, double-blind, placebo-controlled trial","volume":"22","author":"Findling","year":"2012","journal-title":"J\u00a0Child Adolesc Psychopharmacol"},{"key":"10.1016\/j.jaac.2014.11.009_bib24","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1097\/CHI.0b013e3181900404","article-title":"Olanzapine versus placebo in adolescents with schizophrenia: a 6-week, randomized, double-blind, placebo-controlled trial","volume":"48","author":"Kryzhanovskaya","year":"2009","journal-title":"J\u00a0Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.jaac.2014.11.009_bib25","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.schres.2009.10.026","article-title":"Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled study","volume":"116","author":"Hough","year":"2010","journal-title":"Schizophr Res"},{"key":"10.1016\/j.jaac.2014.11.009_bib26","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1089\/cap.2012.0068","article-title":"Ziprasidone in adolescents with schizophrenia: results from a placebo-controlled efficacy and long-term open-extension study","volume":"23","author":"Findling","year":"2013","journal-title":"J\u00a0Child Adolesc Psychopharmacol"},{"key":"10.1016\/j.jaac.2014.11.009_bib27","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1097\/CHI.0b013e3180691779","article-title":"Treatment of Early-Onset Schizophrenia Spectrum Disorders (TEOSS): rationale, design, and methods","volume":"46","author":"McClellan","year":"2007","journal-title":"J\u00a0Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.jaac.2014.11.009_bib28","first-page":"583","article-title":"Double-blind maintenance safety and effectiveness findings from the Treatment of Early-Onset Schizophrenia Spectrum (TEOSS) study","volume":"49","author":"Findling","year":"2010","journal-title":"J\u00a0Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.jaac.2014.11.009_bib29","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1097\/YIC.0b013e328314e1f3","article-title":"Efficacy and safety of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 52-week open-label studies","volume":"23","author":"Emsley","year":"2008","journal-title":"Int Clin Psychopharmacol"},{"key":"10.1016\/j.jaac.2014.11.009_bib30","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1089\/cap.2006.0137","article-title":"Effectiveness and tolerability of olanzapine in the treatment of adolescents with schizophrenia and related psychotic disorders: results from a large, prospective, open-label study","volume":"18","author":"Dittmann","year":"2008","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"10.1016\/j.jaac.2014.11.009_bib31","doi-asserted-by":"crossref","first-page":"763","DOI":"10.4088\/JCP.v63n0903","article-title":"Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder","volume":"63","author":"Kane","year":"2002","journal-title":"J\u00a0Clin Psychiatry"},{"key":"10.1016\/j.jaac.2014.11.009_bib32","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1017\/S1092852900014784","article-title":"The efficacy and safety of lower doses of aripiprazole for the treatment of patients with acute exacerbation of schizophrenia","volume":"11","author":"Cutler","year":"2006","journal-title":"CNS Spectr"}],"container-title":["Journal of the American Academy of Child & Adolescent Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0890856714007990?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0890856714007990?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,27]],"date-time":"2018-09-27T12:52:34Z","timestamp":1538052754000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0890856714007990"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,2]]}},"alternative-id":["S0890856714007990"],"URL":"https:\/\/doi.org\/10.1016\/j.jaac.2014.11.009","relation":{},"ISSN":["0890-8567"],"issn-type":[{"value":"0890-8567","type":"print"}],"subject":[],"published":{"date-parts":[[2015,2]]}}}